Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Panitumumab and CPT-11

"Panitumumab will be administered by IV infusion on day 1 of each cycle just prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg~Irinotecan: 350 or 300 mg/m2. day 1~One treatment cycle is defined as the 21 day period following the commencement of treatment with panitumumab + irinotecan plus additional time, as needed, for the resolution of irinotecan-related toxicities"

Trial Locations (1)

28046

Spanish Cooperative Group for Gastrointestinal Tumour Therapy, Madrid

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

OTHER